With regard to the Adapt product , 95% of cash seems to be from the USA. What is happening in Europe which is an equal market. If our 3D product is as good as I believe it is why is it not being used in Great Ormond Street hospital for children? The FDA have a quick process in cases of obviously best products. I am sure the EU have the same process. What is our highly paid EU boss Mr. Walker doing for his generous salary? Can somebody enquire from the company if our 3D product is being used in Europe and if not how soon might it be introduced? This is where the big margin product can make a difference to our bottom line and to the suffering SP.
AGM 16th Nov, page-35
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.75 |
Change
-0.250(1.67%) |
Mkt cap ! $305.4M | |||
| Open | High | Low | Value | Volume |
| $14.50 | $14.94 | $14.25 | $654.2K | 45.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $14.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.83 | 118 | 1 |
View Market Depth
| Last trade - 12.48pm 05/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |